openPR Logo
Press release

Acute Intermittent Porphyria Market is Projected to Grow at a CAGR of 3.6% from 2023-2033 | IMARC Group

08-24-2023 06:27 PM CET | Health & Medicine

Press release from: IMARC Group

Acute Intermittent Porphyria Market is Projected to Grow at

Acute Intermittent Porphyria Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years 2023-2033
Historical Years 2017-2022
Market Growth (2023-2033) 3.6%

The report offers a comprehensive analysis of the acute intermittent porphyria market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the acute intermittent porphyria market.

Request for a Sample Copy of this Report: 
https://www.imarcgroup.com/acute-intermittent-porphyria-market/requestsample

Market Overview:

The 7 major acute intermittent porphyria markets are expected to exhibit a CAGR of 3.6% during 2023-2033. Acute intermittent porphyria (AIP) refers to a rare genetic disease marked by a deficiency of the porphobilinogen deaminase enzyme, leading to the accumulation of porphyrins in the body. This buildup can lead to numerous symptoms, including abdominal pain, nervous system complications, and skin sensitivity. The acute intermittent porphyria market has witnessed significant growth recently due to various market drivers. In recent years, medical professionals have become more informed about AIP's unique symptoms and diagnostic techniques, resulting in an accurate assessment. This heightened awareness is a primary factor in the surge in demand for treatments and solutions. Investment in research for rare diseases has seen a boost, leading to promising advancements in AIP treatment.

Pharmaceutical companies perceive rare disorders as potential market niches, providing a significant incentive for R&D initiatives in the acute intermittent porphyria realm. Governments and health organizations worldwide have recognized the need for effective treatments for rare diseases. They are now offering incentives like faster approval processes, tax credits, and extended exclusivity periods for orphan drugs. Such policies make the AIP market more attractive for pharmaceutical organizations. Increased collaboration between research institutions, patient advocacy groups, and pharmaceutical companies has expedited clinical trials and shared vital knowledge. This has enriched the understanding of the ailment and accelerated drug development. Strong patient advocacy groups have emerged, focusing on acute intermittent porphyria awareness and fundraising for research. Their efforts have significantly impacted policy-making, ensuring that the needs of acute intermittent porphyria patients are prioritized. Developments in genetic testing and personalized medicine are paving the way for targeted therapies, which is boosting the AIP market. Furthermore, increasing investments to integrate technologically advanced diagnostic tools and speedy drug approvals by the concerned authorities are anticipated to propel the acute intermittent porphyria market in the coming years.

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute intermittent porphyria market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute intermittent porphyria market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current acute intermittent porphyria marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape With Key Players:

The competitive landscape of the acute intermittent porphyria market has been studied in the report with the detailed profiles of the key players operating in the market.

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6980&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Contact Us:

IMARC Group
134 N 4th St
Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Intermittent Porphyria Market is Projected to Grow at a CAGR of 3.6% from 2023-2033 | IMARC Group here

News-ID: 3180587 • Views:

More Releases from IMARC Group

Aluminum Sulfate Manufacturing Plant Cost Report 2024: Business Plan, Raw Material Requirements, and Industry Trends
Aluminum Sulfate Manufacturing Plant Cost Report 2024: Business Plan, Raw Materi …
IMARC Group's report titled "Aluminum Sulfate Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing an aluminum sulfate manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging, and transportation requirements, and more. In addition to
Dry Cell Battery Manufacturing Plant Project Report 2024, Machinery, Cost Analysis and Raw Material Requirements
Dry Cell Battery Manufacturing Plant Project Report 2024, Machinery, Cost Analys …
IMARC Group's report titled "Dry Cell Battery Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing an dry cell battery manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging, and transportation requirements, and more. In
Fiber Glass Manufacturing Plant Project Report- Required Materials and Machinery to Setting up an Unit
Fiber Glass Manufacturing Plant Project Report- Required Materials and Machinery …
IMARC Group's report titled "Fiber Glass Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing a fiber glass manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging and transportation requirements, and more. In addition to
Iron Oxide Manufacturing Plant Report 2024: Business Plan and Raw Material Requirements | IMARC Group
Iron Oxide Manufacturing Plant Report 2024: Business Plan and Raw Material Requi …
IMARC Group's report titled "Iron Oxide Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing an iron oxide manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging, and transportation requirements, and more. In addition to

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug